HB 197 (2017): adding myelitis disorder or disease to the definition of "qualifying medical condition" for the use of cannabis for therapeutic purposes.
Cite this page
Granite Record indexes the General Court’s record; it is not that record. Where a citation allows only one source, cite the General Court — every page here links to what it is drawn from. The date below is the day the page was read.
- MLA
- “HB 197 (2017): adding myelitis disorder or disease to the definition of "qualifying medical condition" for the use of cannabis for therapeutic purposes.” Granite Record, https://graniterecord.org/bill/2017/hb197. Accessed 24 Oct. 2026.
- APA
- Granite Record. (n.d.). HB 197 (2017): adding myelitis disorder or disease to the definition of "qualifying medical condition" for the use of cannabis for therapeutic purposes. Retrieved 24 Oct. 2026, from https://graniterecord.org/bill/2017/hb197
- Chicago
- Granite Record. “HB 197 (2017): adding myelitis disorder or disease to the definition of "qualifying medical condition" for the use of cannabis for therapeutic purposes.” Accessed 24 Oct. 2026. https://graniterecord.org/bill/2017/hb197.
- BibTeX
@misc{bill-2017-hb197, title = {HB 197 (2017): adding myelitis disorder or disease to the definition of "qualifying medical condition" for the use of cannabis for therapeutic purposes.}, howpublished = {Granite Record}, url = {https://graniterecord.org/bill/2017/hb197}, note = {Accessed 24 Oct. 2026} }
HB 197 (2017)
adding myelitis disorder or disease to the definition of "qualifying medical condition" for the use of cannabis for therapeutic purposes.
- Status: Killed
- Term: 2017-2018
- House committee: Health, Human Services and Elderly Affairs
- Subject: Public and Mental Health
The Story
It was introduced on January 4, 2017 and referred to the House Health, Human Services and Elderly Affairs committee. The committee held a public hearing on January 25, 2017. The committee met in executive session on February 22, 2017 to vote on its recommendation. The committee voted unanimously, 17–0, to recommend that the House kill it, and the report was placed on the consent calendar. On March 8, 2017 the House voted to kill it on a voice vote.
Sponsors
- Rep. Robert Renny Cushing (D - Rock 21) (prime sponsor)
- Rep. Karen Umberger (R - Carr 2)
- Rep. Edward Butler (D - Carr 7)
- Rep. Richard Abel (D - Graf 13)
- Sen. Jeb Bradley (R - SD3)
- Sen. Martha Fuller Clark (D - SD21)
Hearings and Sessions
- January 25, 2017, 1:15 PM: public hearing, House Health, Human Services and Elderly Affairs, Representatives Hall
- February 22, 2017, 10:00 AM: executive session, House Health, Human Services and Elderly Affairs, LOB 205
Votes
- March 8, 2017, House: Inexpedient to Legislate — voice vote, passed
The Docket
- January 4, 2017: Introduced 01/04/2017 and referred to Health, Human Services and Elderly Affairs
- January 25, 2017: Public Hearing: 01/25/2017 01:15 PM Representatives Hall
- February 22, 2017: Executive Session: 02/22/2017 10:00 AM LOB 205
- March 8, 2017: Committee Report: Inexpedient to Legislate for 03/08/2017 (Vote 17-0; CC)
- March 8, 2017: Inexpedient to Legislate: MA VV 03/08/2017
Laws It Would Change
Related Bills
- HB 1309 (2016): adding post-traumatic stress disorder to qualifying medical conditions under therapeutic use of cannabis.
- SB 159 (2017): relative to qualifying medical conditions for the purposes of therapeutic cannabis.
- HB 159 (2017): adding fibromyalgia to qualifying medical conditions under therapeutic use of cannabis.
- HB 158 (2017): adding opioid addiction to qualifying medical conditions under therapeutic use of cannabis.